Research programme: recombinant protein therapeutics - Pharming/Transgenic rabbit models

Drug Profile

Research programme: recombinant protein therapeutics - Pharming/Transgenic rabbit models

Alternative Names: Enzyme replacement therapies - Pharming/Transgenic rabbit models; recombinant human-alpha-galactosidase; recombinant human-alpha-glucosidase; rh-alpha-galactosidase; rh-alpha-glucosidase

Latest Information Update: 09 Nov 2015

Price : $50

At a glance

  • Originator Transgenic Rabbit Models
  • Developer Pharming Group NV
  • Class Alpha-glucosidases; Enzymes; Recombinant proteins
  • Mechanism of Action Alpha glucosidase replacements; Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Fabry's disease; Glycogen storage disease type II

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top